Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of SGLT2 Inhibition on Mechanisms of HFpEF
2025-520969-51-00Phase 4Authorised
- Sponsor
- Fundación de Investigación Biomédica del Hospital Universitario de Getafe
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of dapagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Fundación de Investigación Biomédica del Hospital Universitario de Getafe. Primary endpoints: Systolic properties derived from pressure-volume curve analysis: maximum elastance and Diastolic properties derived from pressure-volume curve analysis. Planned start Jan 2025; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2025-520969-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520969-51-00.